

Special Issue

mRNA Vaccine Development against Tropical Diseases

Message from the Guest Editor

Vaccination is the most effective way to prevent infectious diseases. However, complex pathogens such as *Plasmodium* (Malaria), *Trypanosoma cruzi* (Chagas), *Trypanosoma brucei* (African Sleeping Sickness), *Leishmania*, Zika, and others have not been yet effectively tackled with conventional vaccines. mRNA vaccines for COVID-19 demonstrated how plasticity can accelerate the development of new vaccines for complex diseases. We are pleased to announce this Special Issue on “mRNA Vaccine Development against Tropical Diseases”. The issue centers on (1) screening and identifying suitable vaccine candidates using novel in vitro techniques and assays, which allows for a better understanding of the biological and immunological complexities of pathogens, infection, and disease; (2) progress in nucleic acid delivery technology and how it improves vaccine potency and safety; and (3) the regulatory and manufacturer challenges to implementations in the regions (Asia, Africa, Latin America).

Guest Editor

Dr. Cristina Poveda

Baylor College of Medicine, Houston, TX, USA

Deadline for manuscript submissions

closed (28 February 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/121267

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).